Peter A. Pinto, MD, presented “Image-Based Detection and Staging of Prostate Cancer: Is the TRUS Probe Facing Extinction?” at the 11th Urology Today conference on October 27, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Pinto, Peter A. “Image-Based Detection and Staging of Prostate Cancer: Is the TRUS Probe Facing Extinction?.” October 2023. Accessed Jul 2024. https://grandroundsinurology.com/image-based-detection-and-staging-of-prostate-cancer-is-the-trus-probe-facing-extinction/
Image-Based Detection and Staging of Prostate Cancer: Is the TRUS Probe Facing Extinction? – Summary
Peter A. Pinto, MD, explores the possibility of current imaging technology replacing the Transrectal Ultrasound (TRUS) probe in prostate cancer detection and staging. He begins with an overview of the weaknesses of the TRUS probe compared to magnetic resonance imaging (MRI) and MR/ultrasound fusion-guided biopsies in detecting and locating prostate cancer.
However, Dr. Pinto presents a comparison of the detection rates of TRUS-only biopsies with those of MR/ultrasound fusion-guided biopsies. He notes that both of these biopsy approaches can fail to detect low-risk and high-risk prostate cancers, leading to prostate cancer upgrading events.
Dr. Pinto concludes with an examination of the results from MRI-TRUS fusion biopsies. He presents the improved detection and certainty rates of the combined biopsy approach.
About The 11th Urology Today Conference:
Presented by chair Ryan P. Terlecki, MD, FACS, the 11th Urology Today conference was designed to keep urologists, urologic oncologists, and other healthcare providers educated on the most pertinent issues in urology practices. Areas of focus included urologic oncology, men’s health and reconstruction, female urology, pediatric urology, kidney stones and related conditions, and methods of providing the best care amidst the required logistics of the business side of medicine.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Peter A. Pinto, MD, is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute in Bethesda, Maryland. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute at Johns Hopkins Hospital in Baltimore, Maryland. Dr. Pinto is a board-certified urologic surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.
